Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy

NCT01356875 | Unknown Phase 2

• 1 other identifier: SMD-TXAGO
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Transfusional dependence has been associated closely and independently with low survival in patients with myelodysplastic syndrome (MDS), especially in patients at low risk according to IPSS. Treatment of patients with hydralazine + valproic acid as an alternative to treatment with 5-azacytidine has lower cost and possibly as effective with fewer side effects. The objective of this phase II study is to determine the effectiveness of combination therapy with hydralazine + Ac. Valproic compared with best supportive care. The investigators will select 42 patients per group, and after 14 weeks of treatment the investigators will study in both groups the hematological response (transfusion-dependent, hemoglobin, cytogenetics and morphology) and treatment safety (adverse reactions and vital signs) to 1 year after starting treatment. The concentration of hemoglobin, the number of transfusions, platelets, neutrophils and other continuous variables in both groups will be compared by Student t or Mann-Whitney, as appropriate. For comparison of cytogenetic and morphological response and other categorical variables between groups Chi square will be used. And within each group the investigators will compare each of these variables before and after treatment by t-test for paired data or Wilcoxon test.

Conditions

Myelodysplastic Syndrome

Keywords

myelodysplastic syndrome; Transfusion; Hydralazine; valproic acid

Outcome Measures

Primary Outcomes (1)

• change in hemoglobin from baseline in patients who express an erythroid response.

  Independence RBC transfusion requirement for ≥ 8 weeks (56 days) followed by treatment at any time.

  8 weeks

Secondary Outcomes (1)

• Erythroid response according to the criteria of the international working group of SMDs at 24 weeks

  24 weeks

Study Arms (2)

HIDRA/VPA

EXPERIMENTAL

In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.

Drug: HIDRA/VPA

best supportive care (BSC)

ACTIVE COMPARATOR

The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.

Drug: BSC

Interventions

BSC DRUG

The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.

best supportive care (BSC)

HIDRA/VPA DRUG

In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.

HIDRA/VPA

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to understand and voluntarily sign the consent form.
• Age ≥ 18 years at the time of signing the informed consent form.
• Ability and willingness to meet the schedule of study visits and other protocol requirements.
• Documented diagnosis of SMDs according to the criteria of disease risk IPSS intermediate-2, high risk or any risk with transfusion requirements.
• Transfusion-dependent anemia erythrocytes defined as the absence of a period of 56 consecutive days without transfusion of red blood cells for at least 112 days prior (16 weeks).
• Engage both women and men to use highly effective contraception.
• Patients are not candidates for treatment with azacitidine or chemotherapy

You may not qualify if:

• Pregnant or breastfeeding.
• After hematopoietic stem cell transplantation.
• Patients with vitamin B12 deficiency, Folic Acid and Iron
• Any severe psychiatric illness or condition that prevents the patient sign the consent form for the patient or involves an unacceptable risk in case of participating in the study.
• Hypersensitivity to hydralazine and / or AC. Valproic

Sponsors & Collaborators

• Basque Health Service: lead

Study Sites (1)

Txagorritxu Hospital

Vitoria-Gasteiz, Alava, 01009, Spain

Location

MeSH Terms

Conditions

Myelodysplastic Syndromes

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Breno Moreno de Gusmao, MD

CONTACT

+34-945 007000; breno.morenodegusmao@osakidetza.net

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: May 18, 2011
• First Posted: May 20, 2011
• Study Start: September 1, 2011
• Primary Completion: September 1, 2014
• Study Completion: January 1, 2015
• Last Updated: May 20, 2011

Record last verified: 2011-04

Locations

ES (1)